Article

Identification of potential serum markers for endometrial cancer using protein expression profiling.

Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Saitama, 359-8513, Japan.
Journal of Cancer Research and Clinical Oncology (impact factor: 2.56). 09/2009; 136(3):475-81. DOI:10.1007/s00432-009-0680-7
Source: PubMed

ABSTRACT Screening method of endometrial cancer (EC) has not been established yet. Our study was to explore serum biomarkers of EC patients using surface-enhanced laser desorption and ionization-time-of-flight mass spectrometry (SELDI-TOF MS).
Serum samples from 65 EC patients and 40 controls were analyzed by SELDI-TOF MS (training set). Single- and multi-variant analyses were performed to compare protein profiles in serum of EC patients and healthy controls. Subsequently, blind test set including 40 EC patients and 40 controls were analyzed for validation.
A panel of four biomarker candidates were selected in training set analysis. These markers could also distinguish stage I patients from controls. Among them, two biomarkers were purified and identified as apolipoprotein A1 and a modified form of apolipoprotein C1. Screening for blind test set using dual-biomarker analysis yielded a sensitivity of 82% and a specificity of 86%.
Involvement of apolipoproteins with EC is first suggested in this study. In addition to possibility of screening method for EC, findings of these new biomarkers might be related with carcinogenesis or predisposition to EC.

0 0
 · 
0 Bookmarks
 · 
40 Views
  • Source
    Article: Serum Biomarkers for Early Detection of Gynecologic Cancers
    Ueda Yutaka, Enomoto Takayuki, Kimura Toshihiro, Miyatake Takashi, Yoshino Kiyoshi, Fujita Masami, Kimura Tadashi
    [show abstract] [hide abstract]
    ABSTRACT: Ovarian, endometrial, and cervical cancers are three of the most common malignancies of the female reproductive organs. CA 125, historically the most reliable serum marker for ovarian cancer, is elevated in 50% of early-stage ovarian tumors. For endometrial cancers, there are no established serum markers. SCC, which is the best studied serum marker for squamous cell carcinomas, has been unreliable; SCC is elevated in cervical squamous cell carcinomas ranging from 28–85% of the time. Recent proteomics-based analyses show great promise for the discovery of new and more useful biomarkers. In this review, we will discuss the currently utilized serum tumor markers for gynecologic cancers and the novel biomarkers that are now under investigation.
    Cancers. 01/2010;
  • Source
    Article: Altered protein expression in serum from endometrial hyperplasia and carcinoma patients.
    Yi-sheng Wang, Rui Cao, Hong Jin, Yi-ping Huang, Xiao-yan Zhang, Qing Cong, Yi-feng He, Cong-jian Xu
    [show abstract] [hide abstract]
    ABSTRACT: Endometrial carcinoma is one of the most common gynecological malignancies in women. The diagnosis of the disease at early or premalignant stages is crucial for the patient's prognosis. To date, diagnosis and follow-up of endometrial carcinoma and hyperplasia require invasive procedures. Therefore, there is considerable demand for the identification of biomarkers to allow non-invasive detection of these conditions. In this study, we performed a quantitative proteomics analysis on serum samples from simple endometrial hyperplasia, complex endometrial hyperplasia, atypical endometrial hyperplasia, and endometrial carcinoma patients, as well as healthy women. Serum samples were first depleted of high-abundance proteins, labeled with isobaric tags (iTRAQ), and then analyzed via two-dimensional liquid chromatography and tandem mass spectrometry. Protein identification and quantitation information were acquired by comparing the mass spectrometry data against the International Protein Index Database using ProteinPilot software. Bioinformatics annotation of identified proteins was performed by searching against the PANTHER database. In total, 74 proteins were identified and quantified in serum samples from endometrial lesion patients and healthy women. Using a 1.6-fold change as the benchmark, 12 proteins showed significantly altered expression levels in at least one disease group compared with healthy women. Among them, 7 proteins were found, for the first time, to be differentially expressed in atypical endometrial hyperplasia. These proteins are orosomucoid 1, haptoglobin, SERPINC 1, alpha-1-antichymotrypsin, apolipoprotein A-IV, inter-alpha-trypsin inhibitor heavy chain H4, and histidine-rich glycoprotein. The differentially expressed proteins we discovered in this study may serve as biomarkers in the diagnosis and follow-up of endometrial hyperplasia and endometrial carcinoma.
    Journal of Hematology & Oncology 01/2011; 4:15. · 3.99 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

40 controls
 
40 EC patients
 
65 EC patients
 
apolipoprotein A1
 
apolipoprotein C1
 
biomarker candidates
 
blind test
 
dual-biomarker analysis
 
EC patients
 
endometrial cancer
 
ionization-time-of-flight mass spectrometry
 
modified form
 
new biomarkers
 
protein profiles
 
Screening
 
screening method
 
SELDI-TOF MS
 
serum biomarkers
 
specificity
 
surface-enhanced laser desorption